Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
04 févr. 2025 07h30 HE
|
Quoin Pharmaceuticals, Inc.
Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003...
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
23 janv. 2025 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a...
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
14 janv. 2025 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 Weeks Dosing Treatment area expanded from 20% Body...
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
06 janv. 2025 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical Benefits from QRX003 Observed Across All Measured...
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
20 déc. 2024 09h20 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
19 déc. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface...
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
18 déc. 2024 08h18 HE
|
Quoin Pharmaceuticals, Inc.
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only...
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
07 nov. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management...
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
05 nov. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with...
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
31 oct. 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...